⌘K

P

Perceptive Advisors

Crunchbase
Pitchbook
Crunchbase

Deals on record

7

Common Fundraising Type

Series B

K
Kardigan

Biopharmaceutical • Cardiovascular

Perceptive Advisors logo
Sequoia Heritage logo
ARCH Venture Partners logo

Kardigan is a biopharmaceutical company developing personalized medicines for cardiovascular diseases using a proprietary R&D platform.

Series A
$300M
01/10/2025
Article
B
Beta Bionics

Medical Technology • Diabetes Management

Wellington Management logo
RTW Investments logo
Soleus Capital logo
Sands Capital logo

Beta Bionics is a medical technology company that designs, develops, and commercializes autonomous insulin delivery systems to streamline diabetes management.

Series E
$60M
11/15/2024
Article
Z
Zucara Therapeutics

Diabetes • Treatments

Perceptive Advisors logo
Sanofi logo

Zucara Therapeutics Inc. is a life sciences company developing treatments to prevent hypoglycemia in diabetes patients.

Series B
$20M
11/12/2024
Article
A
Axonis Therapeutics

Biotechnology • Neuromedicines

venBio Partners logo
Sofinnova Investments logo
Solasta Ventures logo
SCI Ventures logo

Axonis Therapeutics is a biotechnology company developing novel neuromedicines targeting neurological disorders like epilepsy and pain.

Series A
$115M
10/30/2024
Article
O
Orpyx Medical Technologies

Sensory Insole • Multi-modal sensor technology

Perceptive Advisors logo

Orpyx Medical Technologies develops advanced sensory insoles that use multi-modal sensor technology for continuous remote monitoring to prevent diabetic foot ulcers and amputations.

Equity
$20M
09/25/2024
Article
B
Beta Bionics

Medical Technology • Diabetes Management

Soleus Capital logo
Sands Capital logo
RTW Investments logo
Pura Vida Investments logo

Beta Bionics is a medical technology company that designs, develops, and commercializes autonomous insulin delivery systems to streamline diabetes management.

Series D
$100M
09/01/2023
Article
R
Rapport Therapeutics

Biotechnology • Neurological Disorders

Rapport Therapeutics is a clinical-stage biotechnology company that develops precision neuromedicines for seizure and psychiatric disorders by targeting specific neuroanatomical regions, aiming to provide better alternatives to current treatments by reducing unwanted drug-target interactions.

Series B
$150M
08/23/2023
Article